Antidepressive effect of sodium valproate involving suppression of corticotropin-releasing factor expression and elevation of BDNF expression in rats exposed to chronic unpredicted stress

NeuroReport

Volumn 25, Issue 4, 2014, Pages 205-210

  Qiu, Hong Mei ^a   Yang, Jun Xia ^a   Liu, Dan ^a   Fei, Hui Zhi ^a   Hu, Xiao Ya ^a   Zhou, Qi Xin ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

brain derived neurotrophic factor; corticosterone; corticotrophin releasing factor; depression; sodium valproate

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; VALPROIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSIVE EFFECT; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DRUG EFFECT; HIPPOCAMPUS; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER; GENE EXPRESSION; HIPPOCAMPUS; HYPOTHALAMUS; MALE; NEUROPSYCHOLOGICAL TESTS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STRESS, PSYCHOLOGICAL; TASK PERFORMANCE AND ANALYSIS; VALPROIC ACID;

EID: 84896706936     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000054     Document Type: Article

References (25)

1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-2223.
2. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455:894-902.
3. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 2010; 70:289-297.
4. Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010; 7:243-250.
5. Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C. Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J Psychiatr Res 2010; 44:808-816.
6. Kunugi H, Hori H, Adachi N, Numakawa T. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin Neurosci 2010; 64:447-459.
7. Buckley TM, Schatzberg AF. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab 2005; 90:3106-3114.
8. Davis LL, Ryan W, Adinoff B, Petty F. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 2000; 20:1S-17S.
9. Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 2010; 122:1-9.
10. Molina VA, Volosin M, Cancela L, Keller E, Murúa VS, Basso AM. Effect of chronic variable stress on monoamine receptors: influence of imipramine administration. Pharmacol Biochem Behav 1990; 35:335-340.
11. Chen L, Chen M, Wang F, Keller E, Murúa VS, Basso AM. Antidepressant-like effects of shuyusan in rats exposed to chronic stress: effects on hypothalamic-pituitary-adrenal function. Evid Based Complement Alternat Med 2012; 2012:940846.
12. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47:379-391.
13. Krishnan V, Nestler EJ. Animal models of depression: molecular perspectives. Curr Top Behav Neurosci 2011; 7:121-147.
14. Willner P. The validity of animal models of depression. Psychopharmacology (Berl) 1984; 83:1-16.
15. Brenes Sáenz JC, Villagra OR, Fornaguera Trías J. Factor analysis of forced swimming test, sucrose preference test and open field test on enriched, social and isolated reared rats. Behav Brain Res 2006; 169:57-65.
16. Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005; 11:145-155.
17. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59:1116-1127.
18. Lee BH, Kim YK. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig 2010; 7:231-235.
19. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011; 16:1088-1095.
20. Eren Koçak E, Ertug? rul A. Psychiatric disorders and epigenetics. Tu r k Psikiyatri Derg 2012; 23:130-140.
21. Onishchenko N, Karpova N, Sabri F, Castrén E, Ceccatelli S. Long-lasting depression-like behavior and epigenetic changes of BDNF gene expression induced by perinatal exposure to methylmercury. J Neurochem 2008; 106:1378-1387.
22. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11:1116-1125.
23. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31:464-468.
24. Gillespie CF, Nemeroff CB. Hypercortisolemia and depression. Psychosom Med 2005; 67:26-28.
25. Leng Y, Chuang DM. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006; 26:7502-7512.